Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tafamidis
Drug ID BADD_D02107
Description Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal.[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Indications and Usage Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.[A189708,A189711,L11280]
Marketing Status approved; investigational
ATC Code N07XX08
DrugBank ID DB11644
KEGG ID D09673
MeSH ID C547076
PubChem ID 11001318
TTD Drug ID D04DFR
NDC Product Code 60715-0647; 59651-743; 66039-960; 73435-031; 14501-0102; 58159-079; 60715-4344; 0069-8730; 11014-0390; 69988-0039
UNII 8FG9H9D31J
Synonyms tafamidis | Vyndamax | Vyndaqel | FX 1006A | FX1006A | FX-1006A | tafamidis meglumine
Chemical Information
Molecular Formula C14H7Cl2NO3
CAS Registry Number 594839-88-0
SMILES C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.0010.053027%
Cardiac failure acute02.05.01.0050.003768%Not Available
Cardiac failure congestive02.05.01.0020.012382%Not Available
Cardiac hypertrophy02.04.02.0170.001077%Not Available
Cardio-respiratory arrest02.03.04.002; 22.02.06.0070.001346%Not Available
Cardiogenic shock24.06.02.006; 02.05.01.0030.001077%Not Available
Cardiomyopathy02.04.01.0010.004038%Not Available
Cardiovascular disorder24.03.02.009; 02.11.01.0100.001346%Not Available
Carotid artery stenosis24.04.06.001; 17.08.02.0010.001346%Not Available
Carpal tunnel syndrome17.09.02.0010.005060%Not Available
Cataract06.06.01.0010.001884%
Cataract nuclear06.06.01.0050.000538%Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.002961%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.0070.006729%
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.011251%Not Available
Choking22.12.03.0030.000808%Not Available
Cholecystitis09.03.01.0010.000538%
Cholecystitis acute09.03.01.0030.000538%Not Available
Chromaturia20.02.01.0020.001723%
Circulatory collapse24.06.02.0010.000538%Not Available
Coagulopathy01.01.02.0010.000538%Not Available
Condition aggravated08.01.03.0040.019327%Not Available
Conduction disorder02.03.01.0080.000808%
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.0010.009959%
Coronary artery disease24.04.04.006; 02.02.01.0010.005491%Not Available
Coronary artery occlusion12.02.01.036; 24.04.04.013; 02.02.01.0060.000808%Not Available
Cough22.02.03.0010.010605%
Deafness04.02.01.0010.001992%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 10 Pages